Ipsen Stock Jumps 6% on Strong Q3 Results and Somatuline Boost

Ipsen S.A., the French biopharmaceutical company, saw its stock jump 6% on October 22, 2025, after releasing strong third-quarter results. The rally came as investors cheered solid sales growth and renewed momentum from its blockbuster drug Somatuline. Ipsen’s quarterly report showed not just higher revenues but also stronger margins and improving guidance for the rest of the year.